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Early investigators suggested that ventricular fibrillation without heart failure in acute myocardial
infarction was reliably preceded by warning arrhythmias, and that suppression of such arrhythmias with
intravenous lidocaine could avoid the need for resuscitation. While the efficacy and safety oflidocaine have
been substantiated, the reliability ofwarning arrhythmias as predictorsforprimaryventricularfibrillation has
not. We present data showing that the risk of primary ventricular fibrillation is most dependent on the
patient's age and the interval since the onset of his symptoms, rather than on the presence of warning
arrhythmias. We have estimated that lidocaine prophylaxis would have to be given to about 12 patients in the
highest risk group (patients under age 50 and within six hours of the onset ofsymptoms), compared to about
400 patients in the lowest risk group (patients above age 70 and more than 24 hours since the onset of
symptoms), to prevent one episode of primary ventricular fibrillation in each group. We propose that these
risk stratifications, as adapted to the conditions in specific hospitals, provide the most rational approach to
lidocaine prophylaxis of primary ventricular fibrillation.
The leading American textbooks of medicine recommend routine prophylactic
intravenous lidocaine to prevent ventribular fibrillation in any patient whose acute
myocardial infarction is complicated by ventricular premature contractions which
occur at a rate of more than about three per minute or occurin certain patterns[1,2].
More recently, several authors have suggested that all patients with known or
suspected acute myocardial infarction receive lidocaine prophylaxis for about 48
hours [3-5].
In the following analysis ofthese and other recommendations for the prophylaxis
of primary ventricular fibrillation in acute myocardial infarction, wewill describe the
issues involved and review the pertinent literature. We will show that much of the
present confusion is related to the small sizes oftheindividual studies, to the variable
drug regimens employed, to the failure of many studies to consider factors which
might greatly alter an individual's risk, and to the frequent fear that withholding
prophylaxis from a control group might be unethical. Then, using data relevant to
specific subgroups, we will suggest what we believe is the most rational approach to
the prophylaxis of primary ventricular fibrillation in acute myocardial infarction.
BACKGROUND INFORMATION AND DESCRIPTION OF THE ISSUES
In an attempt to lower the previously standard 35 percent hospital mortality
among patients admitted with acute myocardial infarction [6,7], Day [8,9] and
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Meltzer [10] in the United States, Brown [11] in Canada, and Robinson and Sloman
[12,13] in Australia nearly simultaneously in the early 1960s conceived the idea ofan
intensive coronary care area. Because each ofthese authors' small series included case
reports of patients who were resuscitated from previously fatal arrhythmias, coro-
nary care units (CCUs) quickly gained wide popularity. The subgroup of patients
most likely to be saved by the new CCUs were those with acute myocardial
infarctions (MIs) who developed ventricular fibrillation (VF) in the absence of
congestive heart failure or shock. Such VF, which is termed primary VF in acute MI
and which must be differentiated from "primary VF" without MI [14] and from
secondary VF complicating heart failure or shock in acute MI, will be the subject of
this review.
Although the first CCUs were designed mainly for patients with pre-existing
electrocardiographic evidence of ongoing acute MI, by the middle 1960s many had
already decided that the facilities should also be made available to patients whose
histories suggested acute MI but in whom the diagnosis could not be verified at the
time of admission; these latter patients are commonly termed "rule-out" MIs. By the
late 1960s only about 50 percent of patients admitted to CCUs in New England
actually developed documented MIs [15], and by the middle 1970s only 37 percent of
patients admitted to a large community CCU [16] and only 30 percent of those
admitted to a leading university CCU [17] had documented MIs. Pooled series
[18-23] show that about 40-45 percent of acute MIs will not be complicated by pre-
existing or secondary heart failure to shock; assuming approximately 775,000
patients are admitted annually to United States hospitals with acute MIs [15,24],
approximately 330,000 patients with acute MIs are at risk for primary VF each year.
REVIEW OF THE LITERATURE
As originally conceived, CCUs were to function mainly as resuscitative facilities for
patients with arrhythmias such as primary VF. However, soon after the advent ofthe
CCU, Lown [22] and Julian [25] reported that sudden death from primary VF in
acute MI was commonly preceded by "warning" arrhythmias: more than five
premature ventricular contractions (VPCs) per minute, multiformed or multifocal
VPCs, VPCs occurring on the T wave of the preceding beat, or VPCs appearing in
salvos of two or more. Because of this relationship, Lown proposed that all patients
with definite or "rule-out" infarction who manifested "warning" arrhythmias be
treated with prophylactic lidocaine, and with added procainamide ifneeded, until the
warning arrhythmias disappeared, usually by the third day. Lown never mentioned
exactly how many of his reported patients received prophylaxis because of their
warning arrhythmias, but none of his 77 patients with heart failure nor 73 patients
without heart failure developed ventricular fibrillation after arrival in the CCU.
Because previous studies which did not use prophylactic anti-arrhythmic therapy had
reported a 5-10 percent incidence of ventricular fibrillation in acute MI [9,13,25,26]
the Lown criteria for, and the regimen of, prophylaxis became widely accepted,
especially in the United States.
However, subsequent studies have virtually unanimously disputed the importance
of "warning" arrhythmias. First, continuous electrocardiographic recordings avail-
able for retrospective analysis will show "warning' arrhythmias in 80-90 percent of
patients with acute MI, even though CCU personnel will have noted such arrhyth-
mias in only about 20 percent ofpatients[27,28]. It would seem unreasonable to base
the use of prophylactic medications on the one in five chance that an actual
arrhythmia will be observed. Also, if such arrhythmias occur in 80 percent of
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TABLE I
In-Hospital Primary VF in Acute Myocardial Infarction
Hours After Onset of Symptoms
Author <4-6 <12 <24
Lawrie [20] 17*/24t 22/24 23/24
Church [23] 16/19
Dhurandhar [32] 12/20
Lie [36] 24/36 26/36 30/36
Oliver [37] 10/15
Pentecost [38] 10/10
TOTAL 51/75 64/79 75/90
68% 81% 83%
* Patients who developed primary VF by the end of this time period.
tTotal number of patients who developed primary VF in the sefies.
patients, they are hardly selective for the small proportion who will develop primary
VF. In fact, both Lie [29] and El-Sherif[30] have shown that"warning" arrhythmias
occur just as frequently among patients who do not develop primary VF as among
those who do. Thus it is not surprising that pooled series have observed "warning"
arrhythmias in only about one-third ofpatients who develop primary VF after arrival
in the emergency room [20,23,31-34].
A far better correlate of primary VF is the interval since the onset of the patient's
symptoms. Adgey's series [35], which included the pre-hospital phase of acute MI,
showed that 50 percent of primary VF episodes occurwithin one hour ofthe onset of
symptoms and that the incidence declines exponentially thereafter. Those studies
which begin with the patient's arrival in the emergency room show nearly 70 percent
of primary VF occurring within four to six hours after the onset of symptoms and
over 80 percent occurring by 12 to 24 hours(Table 1). Only Dhurandhar[32] failed to
show at least 83 percent of primary VF within the first 24 hours after onset of
symptoms, but his study is limited by the long mean duration of symptoms prior to
hospital entry (nine hours) which probably also explains why his reported incidence
of primary VF (2.4 percent) is lower than the four to ten percent noted by other
contemporary series. Although five of Dhurandhar's 20 episodes of primary VF
occurred more than 48 hours after the original onset of symptoms, other studies
[33,36,38] note that such late VF is usually related to complications of the original
MI, to extension of the MI, or to reinfarction. In light of the strong correlation
between interval since onset of symptoms and incidence of primary VF, Lown's [22]
success in a group of patients in which only 61 percent had been admitted within 12
hours of the onset of symptoms is not so surprising and cannot be definitely
attributed to his prophylactic regimen.
A second apparently independent correlate of primary VF is the age ofthe patient.
Lie [34] noted a decrease in the incidence of primary VF with advancing age, and
both Lie and Lawrie [20] have found that primary VF is about twice as common in
patients under age 50 as in those aged 50 to 69 (Table 2). Julian [25] also reported
that ventricular fibrillation inthe absence ofsevere heart failure or shock was twice as
common in patients below age 51 as in those aged 51-61. Similarly, Valentine [39]
reported pre-hospital sudden death or VF in acute MI to be three times more likely
below age 50 as in ages 51-69. In patients over age 70, primary VF [34] or VF in the
absence of severe heart failure [25] occurs far less often than in younger patients.
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TABLE 2
Relation between Age and Incidence of Primary VF in Acute Ml
Age of Patient
Below 50 50-69 Above 70
years years years
Lawrie [20] 10*/70t 10/128
Lie [34]** 4/44 13/245 1/111 (0.9%)
Cumulative Totals 14/114 (12.3%) 23/ 373 (6.2%)
*Number of patients who developed primary VF.
tNumber of patients in this age range.
**Chi-square of linear trend = 5.86 (0.01 < p < 0.05).
Only Dhurandhar[32], with his long mean duration since onset ofsymptoms, has not
noted a correlation between age and primary VF; however, Dhurandhar's article does
not include actual numbers.
There is no clear correlation between incidence of primary VF and the sex of the
patient or the location of the infarction (anterior versus inferior). Individual series
have shown no difference in the incidence of primary VF in transmural versus
nontransmural MI, but if the data from the three largest series could be pooled,
transmural MIs would seem to be associated with a higher risk [40-42]. However,
none of these three studies provide enough information on patients' ages orintervals
since the onset of symptoms for transmural MI to be considered an independent risk
factor for primary VF. Despite early emphasis on the importance of VPCs which
interrupt the T wave of the preceding beat [13,43], recent studies have shown that
later VPCs also commonly trigger ventricular tachycardia and primary VF
[29,30,44].
Efficacy ofAnti-Arrhythmic Prophylaxis ofPrimary VF in Acute MI
The numerous randomized controlled trials of lidocaine prophylaxis of primary
VF in acute MI are shown in Table 3. Because of the influence of Lown's original
report, the five series in Section A of Table 3 treated "control" patients if they
developed warning arrhythmias. Some of these series in Section A showed fewer
VPCs and fewer salvos or runs of VPCs inthe universally treated groups[45,48], but
universal prophylaxis of patients without heart feailure or shock was no better at
preventing primary VF than was lidocaine reserved for patients with warning
arrhythmias. Also, the overall 4.4 percent incidence of primary VF in the treated
groups of Section A of Table 3 is not substantially different than the 5.6 percent
incidence of primary VF in the control patients in other studies where lidocaine was
not given at all (Section B of Table 3). These controlled studies seem to make two
points: first, the potentialhazards ofwithholding lidocaine until warningarrhythmias
are observed is substantiated; and second, low-dose lidocaine is ineffective prophy-
laxis for primary VF. This latter point is not surprising in light of recent data in
patients without heart failure: lidocaine rates of 35 to 88 ug/kg/min (which
translates to rates of 2.5 to 6.2 mg/min for a 70 kg patient) were required to reach
minimum (2.4 ug/ml) and maximum (6.0 ug/ml) therapeutic steady-state lidocaine
levels, respectively [52]. In summary, among all the randomized trials in hospitalized
patients, only Lie's series [31] (Section B ofTable 3), which used the highest dose of
lidocaine in patients who were all under 70 years of age and had all been admitted
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TABLE 3
Controlled Trials of Lidocaine Prophylaxis of Primary VF after Hospital Arrival
Mean No. of No. of Controls
Hours since Treated with Incidence of Incidence of
Onset of Dose Lidocaine for Primary VF in Primary VF in
Symptoms Loading Maintenance warning VPCs Control Group Treated Group
A. Control Group Treated if Warning VPC's
Mogensen [45] ? 75 mg 2 mg/minute 24/37 1/37 0/42 (N.S.)*
IV
Darby [46] About 5 200 mg 2 mg/minute 16/100 3/100 4/103 (N.S.)
IM
Church [47] < 4 50-75 mg 2 mg/minute 10/44 3/44 4/42 (N.S.)
IV
Pitt [48] ? Variable 2.5 mg/minute 34/114 0/114 0/108 (N.S.)
Bennett [49] 4-12 60 mg 0.5-1 mg/minute 36/125 7/125 16/251 (N.S.)
IV
TOTALS 120/420 14/420 24/546
(29%) (3.3%) (4.4%)
B. Controls Not Treated for Warning VPC's
Bleifield [50] 10 100 mg 1.0-2.8 mg/ 0 2/49 0/41 (N.S.)
IV minute
Chopra [51] 14 50-150 mg 1-2 mg/rminute 0 0/43 I/39 (N.S.)
IV
Lie [31] All < 6 100 mg 3 mg/minute 0 9/105 0/107 (p < 0.002)
IV
TOTALS 11/197 (5.6%) 1/187 (0.5%)
*Not statistically significant.
within six hours of the onset of symptoms, showed a significant reduction in primary
VF.
The largest reported experience with prophylactic lidocaine therapy is not in the
context of a randomized trial but rather from the clinical observations of Wyman
[53], who had originally noted VF in the absence ofpulmonary edema or shock in 8
of 139(6.5%) patientstreated with prophylactic oral quinidine or procainamide. Over
the next seven years, Wyman adopted a policy oflidocaine prophylaxis (which, in the
19 percent of patients with persistent VPCs, was augmented by intravenous procain-
amide) and reduced the incidence of VF to none of the 145 patients in whom the
criteria for prophylaxis were warning arrhythmias, one of the 270 in whom the
criterion for prophylaxis was a single VPC, and two of the 611 patients in whom the
sole criterion for prophylaxis was the suspicion of an acute MI. In a subsequent
report [16], Wyman's prophylaxis regimen (a 75 mg bolus of lidocaine followed by a
2 mg perminutedrip, with additional lidocaine or procainamide for persistent VPCs)
resulted in only six episodes of primary VF among 1,000 acute MI patients, 31
percent of whom were seen within one hour of onset of symptoms. Another six
patients developed primary VF in the emergency room before prophylaxis could be
started. Wyman's impressively low 0.3 percent [53] to 0.6 percent [16] incidence of
primary VF after initiation of lidocaine prophylaxis is similar to the results of Pitt
[48] and Lie [31] who used high-dose lidocaine without procainamide and without
concern for warning arrhythmias.
There are only two major reports of lidocaine in the pre-hospital phase of acute
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MI. Adgey's uncontrolled observations showed that only 60 percent of patients
responded to a 100 mg intravenous bolus with a decrease in frequency of VPCs but
did not comment on prevention of primary VF [35]. In a controlled trial, Valentine
[39] reported a significant reduction in "early deaths" (which he defined as docu-
mented VF or "sudden death" regardless of whether resuscitation was successful, or
an actual death from power failure, within two hours of initial medical attention) in
patients given 300 mg intramuscular prophylactic lidocaine. However, closer analysis
of his results reveals that the differences inarrhythmic "sudden death" were not quite
statistically significant(0.05<p<O.10) and that all three patients with documented
primary VF were successfully resuscitated. Still, the potential benefits of lidocaine
were especially impressive among those less than 50 years of age: five of 24 controls
developed "sudden death" compared to none of 37 treated patients.
In summary, lidocaine in large doses can potentially reduce the incidence of
primary VF from 5-10 percent to about 0.5 percent. Wyman [16,53] has been very
successful with his carefully regulated regimen, but a program of high-dose universal
lidocaine prophylaxis without additional procainamide or other drug alterations for
persistent VPCs seems easier and equally efficacious for the prevention of primary
VF [31,48].
Risks and Side Effects of Lidocaine Prophylaxis of Primary VF in Acute MI
None of the major studies of lidocaine prophylaxis in patients with acute MI not
complicated by heart failure or shock has reported any important cardiac side effects
or any lidocaine-related deaths. However, standard intravenous infusions of 2.5 to
3.0 mg per minute for 48 hours will cause transient neurological side effects in about
16 percent of patients under the age of 70 [31,48]; most of these side effects will be
minor (drowsiness, facial numbness, speech disturbances, and dizziness), but seizures
or coma may also occur[48,53]. If, on the other hand, the infusion is regulated by a
constant infusion pump, seizures and coma are exceedingly rare in patients without
heart failure or hepatic dysfunction [31,53]. Lie [31] noted that his minor side effects
were three times more frequent in patients 60-69 years old compared to those below
age 60; no good data are available specifically for patients over age 70.
Recent data [54] have shown that lidocaine elimination is impaired during
prolonged intravenous infusion. After 24 hours of continuous infusion in patients
without heart failure, lidocaine blood levels can be maintained with doses only about
one-half those required during the first 24 hours.
Immediate and Post-Discharge Prognosis After Primary VF in Acute MI
Early reports, which did not usually distinguish between primary and secondary
VF, quoted successful immediate resuscitation in only 25-30 percent of patients with
VF [25]. In 1973, Wyman [55] reported a 53 percent survival if VF developed in the
absence of severe pump failure. If, however, we continue to limit our concern to true
primaryVF, Table 4 shows a unanimously high rate of successful resuscitation. The
success rate, which averaged 94 percent, wasjust as high in United States community
hospitals without housestaffs but with well-trained nursing staffs [16,23] as in
teaching hospitals. The series also show that 87 percent of patients with primary VF
survive to leave the hospital; at least half of those who die in the hospital after the
originally successful resuscitation do so despite vigorous anti-arrhythmic therapy.
After hospital discharge, pooled series [13,21,56-58] show excellent six-month
survival (98 percent) and reasonable one-year survival (average 87 percent). Only
Conley [21] has described a suggestive, but not statistically significant, decrease in
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TABLE 4
Outcome of Patients Who Develop Primary VF in Acute Ml after Hosptial Arrival
No. of patients No. of patients
No. of patients successfully surviving to
Author with primary VF resuscitated leave hospital
Meltzer [1O] 9 9 ?
Goble [13] 5 5 5
Wyman [16] 12 12 12
Lawrie [20] 24 22 20
Church [23] 19 18 18
Darby [46] 7 ? 5
Lie [31] 9 8 8
Lie [34] 18 17 17
Pentecost [38] 10 9 7
TOTALS 100/106=94% 92/104=88%
one-year survival in patients who have been resuscitated from primaryVF compared
to those acute MI patients without heart failure or shock who did not develop
primary VF. Even if one-year mortality is higher in the patients who had primary VF,
it is not at all clear that this increased outpatient mortality is a result of the original
in-hospital episode of primary VF.
RISK STRATIFICATION
Using the data we have summarized, we can estimate the risk of primary VF in
acute MI if we know two independent factors: the patient's age and the interval since
the onset of his symptoms (see Appendix). Based on these data, Table 5 shows the
approximate number of patients in various subgroups who would have to receive
lidocaine prophylaxis in each time period to prevent one episode of primary VF
during that specified time period. Based on the rates we have reviewed for resuscita-
tion and survival after primary VF, each number in Table 5 could be multiplied by
TABLE 5
Approximate Number of Patients Who Must Receive Prophylaxis to Prevent One Episode of Primary VF*
Time since onset of symptoms
Age below 50 years
Indicationfor prophylaxis < 6h 6-24h > 24h
All MI 12 54 48
All Ml or rule-out MI 30 135 120
Age 50-69 years
Indicationfor prophylaxis < 6h 6-24h > 24h
All Ml 24 110 96
All Ml or rule-out MI 60 275 240
Age 70 or more years
Indicationfor prophylaxis < 24h > 24h
All MI 100 400
All MI or rule-out Ml 250 1000
*Based on our assumptions, only about one patient in 8.3 with primary VF will die in the hospital as a direct or
indirect result of the arrhythmia. (See text and Table 4.)
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8.3 to estimate how many patients must receive lidocaine prophylaxis to prevent each
death from primary VF. Note that the increased "benefit" of prophylaxis after 24
hours compared to during the interval between six and 24 hours is partly
artifactual-because of the larger number of hours in the time period-and partly
related to reinfarction or extension of infarction [33,36,38]. Actually, the benefit per
hour of prophylaxis decreases progressively and dramatically with time; when an
individual patient enters a lower risk subgroup, his expected benefits from prophy-
laxis decline.
Although our risk estimates are carefully based on the principles which should
guide the retrospective analysis of pooled data [59], several potentially confounding
factors must be considered. First, data on patients who never received lidocaine for
any indication are available largely from The Netherlands. Their precise applicability
to the United States is unproved. Unfortunately, to prove our estimates prospectively
in the high-risk subgroups may be considered unethical, and to prove the estimates in
the low-risk subgroups would be logistically impractical. (For example, if our
estimates are correct, to show a statistically significant decrease in primary VF and
then in death from primary VF among patients over age 70 who receive routine
lidocaine prophylaxis for the first 24 hours after the onset of symptoms, randomized
controlled trials might require 4,400 and 20,000 patients, respectively.) Second, data
on the importance of the interval since the onset of symptoms are less plentiful in
patients over age 70 than in younger patients because: (a) in the era before the
common use of lidocaine, patients over age 70 were not admitted to many CCUs; and
(b) recent randomized trials, whose control groups represent the only reliable,
published sources of patients never receiving lidocaine, have excluded patients over
age 70. According to Lie (personal communication), about 80 percent ofprimary VF
in patients over age 70 occurs within 24 hours of the onset of symptoms. We have
used Lie's experience to calculate our risk estimates for patients over age 70, but these
estimates are surely less precise than those made for younger patients. Third, our
estimate of zero serious side effects of lidocaine presumes constant infusion systems;
standard intravenous drips will be associated with such frequent serious side effects
(up to four percent) as to outweigh the potential benefits in patients at very low risk
for primary VF. Fourth, while well-trained nurses will do as well as housestaff in
resuscitating patients from primary VF, if staffis marginal during part ofthe day, the
risk of death from an episode of primary VF might be substantially higher than
quoted in our estimates. Fifth, even when quickly converted, primary VF may well
have deleterious psychological consequences. We must again emphasize that while
these risk estimates may apply to over one million patients admitted yearlyfor MI or
rule-out MI in the absence of heart failure, data are insufficient to stratify risk of VF
in those with heart failure.
RECOMMENDATIONS
Although the impact of routine aggressive lidocaine prophylaxis for subgroups of
patients at substantial risk for primary VF may not be obvious in any one individual
hospital, lidocaine prophylaxis could prevent about 15,000 episodes of primary VF
each year nationwide. Using our risk estimates as a guide to therapy would avoid
needlessly subjecting many times that number of very low-risk patients to potential
lidocaine toxicities.
We cannot recommend any precise risk of primary VF which should be used as a
cutoff point for prophylaxis until we have better estimates of the side effects of
lidocaine in larger numbers of patients, better knowledge of the success rate for
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resuscitation in specific hospitals, and better ways to stratify the chances that
infarction will be documented in an individual patient with a "rule-out" MI. For the
present we recommend:
1. Routine lidocaine prophylaxis for primary VF should be given as soon as
possible when a patient who is below age 70 and who is within six hours ofthe
onset ofsymptoms is diagnosed in an emergency room as having an acute MI
or probably even a high likelihood of an acute MI. Assuming normal hepatic
function, the dose should be at least a 75-100 mg bolus followed by about a 35
ug/kg/min infusion.
2. Routine lidocaine prophylaxis of primary VF does not seem warranted in
patients who are over age 70 and (a) are more than 24 hours after the onset of
symptoms or (b) have a low probability of an actual MI.
3. For patients in other subgroups, we can only say that our estimates ofthe risk
of primary VF in acute MI combined with whatever cutoff point seems most
appropriate in an individual hospital are a better guide for deciding which
patients should receive prophylaxis than the small series originally reported by
Lown [22], the standard recommendations of the leading medical textbooks
[1,2], or the recent recommendation that every hospital should give routine
lidocaine prophylaxis for afull 48 hours afterhospitaladmission to all patients
[3,4] orjust to patients below 70 years of age [5].
4. "Warning" arrhythmias do not reliably predict which patients are at high risk
for primary VF and their presence or absence should not be used as the guide
for institutingprophylaxis. After about 48 hours since the onset ofsymptoms,
or in the presence of heart failure, hypotension, recurrent pain, orarrhythmia-
associated symptoms, "warning" VPCs may beimportant correlates ofsecond-
ary VF or hemodynamic compromise and should be suppressed.
5. If lidocaine is continued for more than 24 hours, the infusion rate should be
decreased by about 50 percent because of the reduced clearance of lidocaine
after prolonged infusions. Otherwise, the risks of lidocaine toxicity will be
increasing substantially with time while the risks of primary VF are declining.
Lidocaine is a usually safe drug and is of proved efficacy in reducingtheincidence
of primary VF in the CCU setting. We believe our estimates emphasize (a) how
certain patient subgroups are most likely to benefit from lidocaine prophylaxis; and
(b) how other subgroups at minimal risk for primary VF may have more complica-
tions than benefits from lidocaine prophylaxis.
APPENDIX
Assumptionsfor Calculations ofPotential Risks and Benefits ofLidocaine
Prophylaxis
1. The basic risk of primary VF is 8.6 percent in patients who receive no
antiarrhythmic prophylaxis, are less than 70 years ofage, and are admitted within six
hours of the onset of symptoms of a new myocardial infarction without "congestive
heart failure, cardiogenic shock, complete atrioventricular block, persistent brady-
cardia (rate less than 50 beats per minute), persistent ventricular tachycardia or
ventricular fibrillation on admission" [31].
2. The age-related ratios for primary VF are as reported in Table 2: two to one
for under age 50 compared to ages 50-69 [24,34], and 6.5 to one for all below age 70
compared to age 70 and higher [34]. Considering the age distribution ofhospitalized
patients with acute MI [60] and the probably increased prevalence of heart failure in
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elderly patients with infarction[20,61-63], our estimated risks for primary VF are: 13
percent for patients under age 50, 6.5 percent for those aged 50-69, and 1.3 percent
for patients aged 70 and above. These estimates for each age group are about as high
as reported in any large series of patients who reach the hospital.
3. As noted in Table 1, for patients below age 70 about 68 percent ofprimaryVF
will occur by six hours after the onset of symptoms, another 15 percent will occurby
24 hours, and nearly all ofthe remainder will occur by48 hours. For patients over age
70, far fewer specific data are available, but an approximately equivalent 80 percent
of primary VF will appear within 24 hours of the onset of symptoms (Lie, personal
communication).
4. Lidocaine given in the only clearly effective doses, 75-100 mg bolus followed
by a 2.5-3.0 mg her minute infusion, will reduce the rate of primary VF from 8.6
percent to 0.5 percent in patients below age 70 and by a similar ratio in other types of
patients [16,31,48].
5. No patients will die as a result of lidocaine prophylaxis in the absence ofheart
failure or shock.
6. About 60 percent ofthe patients who were originally thought to be at potential
risk for primary VF in acute MI will not actually have infarction [15,17]; the risk of
in-hospital primary VF in these patients is assumed to be zero.
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